AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 16 analysts
Fundamentals
Fundamentals institutional score is 75 using growth durability 74.6.
Valuation
Valuation institutional score is 34 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 65 using mean target upside 6.4%; dispersion penalty 10.4; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 64 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 11 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 36.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.71). Confidence: 76%.
Live forward EPS implies next-12-month EPS of ₹16.86. Applying the stock's normalized valuation corridor produces a fair range of ₹1,375.44 to ₹2,257.55, with base value near ₹1,963.68 (+139.6% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹16.86
Forward P/E
48.6x
Base Fair Value
₹1,963.68
Fair Range
₹1,375.44 - ₹2,257.55
Upside To Base
+139.6%
Estimate Source
Live forward EPS
Growth Estimate
-46.9%
5Y Average
91.18
Current
158.73
Overvalued
133.90
Undervalued
81.58
5Y Average
27.88
Current
49.03
Overvalued
37.46
Undervalued
17.88
5Y Average
4.43
Current
7.78
Overvalued
5.95
Undervalued
2.84
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 142.3x Premium | +94% vs avg | +47.9% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 71.4x Fair | -2% vs avg | +6.9% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.4x Undervalued | -38% vs avg | +6.8% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.9x Undervalued | -20% vs avg | +7.6% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 86.7x Premium | +18% vs avg | +48.1% |
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 69.3x Fair | -5% vs avg | +1.4% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 45.8x Undervalued | -37% vs avg | +95.4% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 66.2x Fair | -10% vs avg | +23.2% |
KRISHNA INST OF MED SCI L trades at a premium (159.9x vs peer avg 73.2x), implying higher growth or quality expectations from the Hospitals & Diagnostic Centres cohort. Peers include ASTER DM QUALITY CARE LTD, GLOBAL HEALTH LIMITED, NARAYANA HRUDAYALAYA LTD. — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹484 CrJun 2026Latest net profit
₹66 CrJun 2026Latest EPS
₹1.58Jun 2026Net margin
24.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 299 | 316 | 302 | 305 | 327 | 363 | 348 | 346 | 373 | 430 | 442 | 456 | 484 |
| Expenses + | 207 | 218 | 215 | 218 | 234 | 252 | 245 | 237 | 276 | 318 | 314 | 326 | 365 |
| Operating Profit | 92 | 98 | 87 | 86 | 94 | 111 | 103 | 109 | 98 | 112 | 128 | 130 | 118 |
| OPM % | 31% | 31% | 29% | 28% | 29% | 31% | 30% | 31% | 26% | 26% | 29% | 29% | 24% |
| Other Income + | 4 | 4 | 4 | 4 | 5 | 7 | 21 | 35 | 12 | 12 | 14 | 11 | 31 |
| Interest | 0 | 0 | 1 | 2 | 4 | 5 | 7 | 8 | 12 | 18 | 22 | 27 | 33 |
| Depreciation | 12 | 13 | 13 | 20 | 14 | 14 | 15 | 15 | 18 | 20 | 23 | 26 | 27 |
| Profit before tax | 84 | 89 | 78 | 68 | 82 | 99 | 102 | 120 | 80 | 86 | 98 | 89 | 89 |
| Tax % | 25% | 26% | 25% | 29% | 26% | 27% | 25% | 22% | 26% | 26% | 26% | 26% | 25% |
| Net Profit + | 63 | 66 | 58 | 48 | 61 | 72 | 76 | 94 | 59 | 64 | 72 | 66 | 66 |
| EPS in Rs | 1.56 | 1.65 | 1.46 | 1.20 | 1.52 | 1.80 | 1.91 | 2.34 | 1.47 | 1.59 | 1.81 | 1.65 | 1.58 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation Of Receipt Of The In-Principle Approval From BSE Limited And The National Stock Exchange Of India Limited